A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | MicrobiomeTrials
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
RecruitingPHASE1, PHASE2INTERVENTIONAL
Trial Details
Start: 2021-09-16Est. Completion: 2026-11
Enrollment target: 246 participants
Locations
University of Alabama At Birmingham Hospital, Birmingham, Alabama, United States
City of Hope National Medical Center, Duarte, California, United States
City of Hope Irvine Lennar, Irvine, California, United States
University of Miami, Miami, Florida, United States
Emory University Winship Cancer Center, Atlanta, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
Washington University School of Medicine, St Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Memorial Sloan Kettering Cancer Center Mskcc, New York, New York, United States
The James Cancer Hospital and Solove Research Institute At Ohio State University, Columbus, Ohio, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
University of Washington, Seattle, Washington, United States
University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
Other microbiome trials you might be interested in